Erschienen in:
Current Opinion in Organ Transplantation, 26 (2021) 4, Seite 381-389
Sprache:
Englisch
DOI:
10.1097/mot.0000000000000900
ISSN:
1087-2418;
1531-7013
Entstehung:
Anmerkungen:
Beschreibung:
<jats:sec>
<jats:title>Purpose of review</jats:title>
<jats:p>To define recent changes and future directions in the practice of pancreas transplantation (PT). Two major events have occurred in the past 18 months: COVID-19 pandemic, and the first world consensus conference on PT. Several innovative studies were published after the consensus conference.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Recent findings</jats:title>
<jats:p>During COVID-19 pandemic PT activity decreased. COVID-19 in transplant recipients increases mortality rates, but data from kidney transplantation show that mortality might be higher in waitlisted patients.</jats:p>
<jats:p>The world consensus conference provided 49 jury deliberations on the impact of PT on management of diabetic patients and 110 practice recommendations.</jats:p>
<jats:p>Recent evidence demonstrates that PT alone is safe and effective, that results of simultaneous pancreas and kidney (SPK) remain excellent despite older recipient age and higher prevalence of type 2 diabetes, that use of hepatitis C virus (HCV)-positive donors into HCV-negative recipients is associated with good outcomes, and that use of sirolimus as primary immunosuppressant and costimulation blockade does not improve results of SPK.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Summary</jats:title>
<jats:p>COVID-19 pandemic and the first world consensus conference on PT were major events. Although COVID-19 pandemic should not reduce PT activity in the future, a major positive impact on both volume and outcomes of PT is awaited from the proceedings of the world consensus conference.</jats:p>
</jats:sec>